Dealroom, a leading data provider for startups and investors, has recently released its European Spinout Report 2025. The report highlights the rapid growth and success of European deep tech and life sciences spinouts, with 76 companies reaching impressive milestones of either $1 billion valuations, $100 million in revenue, or both.
Spinouts, also known as spin-off companies, are startups that are created from technology or intellectual property developed within a larger parent company. They have been gaining popularity in the European startup ecosystem, with a record number of 1,500 spinouts being created in the last five years. These companies are disrupting industries and driving innovation, and the latest report by Dealroom proves that they are also achieving remarkable success.
According to the report, the majority of the 76 spinouts with billion-dollar valuations or $100 million in revenue are from the United Kingdom, followed by Germany, France, and Switzerland. This not only showcases the strength and diversity of the European startup scene but also highlights the potential for spinouts to become major players in the global market.
One of the standout spinouts mentioned in the report is Darktrace, a UK-based cybersecurity company that has reached a valuation of $1.65 billion. Darktrace was created by a team of mathematicians and government intelligence experts from the University of Cambridge, and its cutting-edge technology uses Artificial Intelligence to detect and respond to cyber threats in real-time. The company has achieved impressive success since its spinout in 2013 and is now a household name in the cybersecurity industry.
Another notable spinout is CureVac, a German biotech company that focuses on developing mRNA-based vaccines and therapies. With a valuation of $1.7 billion, CureVac has made significant strides in the fight against COVID-19, with its vaccine candidate currently in phase 3 clinical trials. The company was spun out of the University of Tübingen in 2000 and has since become a leader in the field of mRNA technology.
The success of these spinouts is a testament to the growing interest and investment in deep tech and life sciences startups in Europe. These companies are at the forefront of technological advances and have the potential to revolutionize industries, create jobs, and contribute to economic growth.
In addition to the impressive valuations and revenue numbers, the report also highlights the positive impact that spinouts have on job creation. The 76 spinouts mentioned in the report have collectively created over 10,000 jobs, with an average of 130 employees per company. This not only provides employment opportunities but also attracts top talent and boosts the overall competitiveness of the European startup ecosystem.
The success of spinouts is also reflected in the increasing interest from investors. In 2020, spinouts raised a record-breaking $7.3 billion in funding, a significant increase from the $4.7 billion raised in 2019. This shows that investors are recognizing the potential of spinouts and are willing to invest in their growth and development.
The European Spinout Report 2025 also sheds light on the potential for future success for these companies. The report predicts that by 2025, there will be over 200 spinouts with billion-dollar valuations or $100 million in revenue, and they will collectively create over 25,000 jobs. This is a promising outlook for the European startup scene and highlights the potential for spinouts to continue driving innovation and growth in the region.
In conclusion, the European Spinout Report 2025 by Dealroom is a testament to the success of deep tech and life sciences spinouts in Europe. These companies have achieved impressive valuations and revenue numbers, created thousands of jobs, and attracted significant investment. As we look towards the future, it is clear that spinouts will continue to play a crucial role in shaping the European startup ecosystem and driving innovation across industries.
